Jan 8 BioMarin Pharmaceutical Inc
announced on Sunday what it called "positive interim results"
from its study of a gene therapy treatment for severe
The company said the average annualized bleeding rate had
dropped 91 percent for six patients who were receiving the
highest treatment dose and were previously on a particular
Analyst John Scotti of Evercore ISI said in a research note
that the report was "encouraging, and may help to quell
investors concerns." The report updated one the company issued
The company made the announcement ahead of a presentation on
Monday at the JPMorgan annual healthcare conference.
(Reporting by David Henry in New York; Additional reporting by
Deena Beasley in Los Angeles; Editing by Peter Cooney)